HER2阴性乳腺癌-话题@MedSci

#HER2阴性乳腺癌#

16篇内容 | 657人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2130425, encodeId=7beb213042548, content=<a href='/topic/show?id=38538e43be' target=_blank style='color:#2F92EE;'>#HER2阴性乳腺癌#</a>早期、局部晚期乳腺癌患者可以从新辅助化疗（NAC；手术前给予的治疗）中受益，主要是因为治疗期间和治疗后的肿瘤反应可以测量并用于为后续治疗决定提供信息。达到病理完全反应（pCR）的患者，主要是乳房和区域淋巴结中没有侵袭性癌症的患者，与NAC后残留癌症患者相比，转移性复发和死亡的风险显著降低。, objectTitle=HER2阴性乳腺癌, objectType=topic, longId=8743, objectId=null, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=null, replyNumber=0, likeNumber=31, createdTime=2023-05-06, rootId=0, userName=yangchou, userId=88b489038, projectId=1, avatar=, status=1, hasArticle=0, attachment=null, ipAttribution=, moduleDTOList=null, followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=2028131, encodeId=2374202813136, content=<a href='/topic/show?id=38538e43be' target=_blank style='color:#2F92EE;'>#HER2阴性乳腺癌#</a>, objectTitle=2022 ASCO：多西他赛和环磷酰胺辅助治疗HER2阴性乳腺癌的现实经验, objectType=article, longId=728385, objectId=dc7ae283851f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc7ae283851f, replyNumber=0, likeNumber=0, createdTime=2023-03-26, rootId=0, userName=feather78, userId=3679417, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc7ae283851f, moduleTitle=2022 ASCO：多西他赛和环磷酰胺辅助治疗HER2阴性乳腺癌的现实经验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc7ae283851f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028129, encodeId=63a4202812997, content=<a href='/topic/show?id=38538e43be' target=_blank style='color:#2F92EE;'>#HER2阴性乳腺癌#</a>, objectTitle=Chin J Cancer Res：阿帕替尼单药或联合治疗HER2阴性乳腺癌伴有胸壁转移患者的疗效：多中心II期临床研究, objectType=article, longId=292393, objectId=a3232923933c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3232923933c, replyNumber=0, likeNumber=55, createdTime=2022-09-24, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3232923933c, moduleTitle=Chin J Cancer Res：阿帕替尼单药或联合治疗HER2阴性乳腺癌伴有胸壁转移患者的疗效：多中心II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a3232923933c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028130, encodeId=8e5f202813056, content=<a href='/topic/show?id=38538e43be' target=_blank style='color:#2F92EE;'>#HER2阴性乳腺癌#</a>, objectTitle=Ther Adv Med Oncol：Bendamustine (苯达莫司汀)联合卡培他滨治疗经治的HER2阴性乳腺癌患者的疗效, objectType=article, longId=293430, objectId=627129343025, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=627129343025, replyNumber=0, likeNumber=47, createdTime=2022-05-13, rootId=0, userName=feather78, userId=3679417, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=627129343025, moduleTitle=Ther Adv Med Oncol：Bendamustine (苯达莫司汀)联合卡培他滨治疗经治的HER2阴性乳腺癌患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=627129343025)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028128, encodeId=2f0a20281289a, content=<a href='/topic/show?id=38538e43be' target=_blank style='color:#2F92EE;'>#HER2阴性乳腺癌#</a>, objectTitle=Br J Cancer：PI3K信号通路激活导致HER2阴性乳腺癌的eribulin耐药性的产生, objectType=article, longId=208867, objectId=cb1020886ea9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb1020886ea9, replyNumber=0, likeNumber=40, createdTime=2022-02-24, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb1020886ea9, moduleTitle=Br J Cancer：PI3K信号通路激活导致HER2阴性乳腺癌的eribulin耐药性的产生, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb1020886ea9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028127, encodeId=984b202812e24, content=<a href='/topic/show?id=38538e43be' target=_blank style='color:#2F92EE;'>#HER2阴性乳腺癌#</a>, objectTitle=AACR 2020：Durvalumab+奥拉帕利+紫杉醇用于高危HER2阴性乳腺癌新辅助治疗创新高, objectType=article, longId=193172, objectId=24cd1931e229, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=24cd1931e229, replyNumber=0, likeNumber=46, createdTime=2020-05-21, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=24cd1931e229, moduleTitle=AACR 2020：Durvalumab+奥拉帕利+紫杉醇用于高危HER2阴性乳腺癌新辅助治疗创新高, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=24cd1931e229)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028125, encodeId=7e6e20281251f, content=<a href='/topic/show?id=38538e43be' target=_blank style='color:#2F92EE;'>#HER2阴性乳腺癌#</a>, objectTitle=β受体拮抗剂是否可以延长晚期HER2阴性乳腺癌患者生存时间？, objectType=article, longId=113380, objectId=f8ed113380c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8ed113380c7, replyNumber=0, likeNumber=46, createdTime=2017-09-30, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8ed113380c7, moduleTitle=β受体拮抗剂是否可以延长晚期HER2阴性乳腺癌患者生存时间？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8ed113380c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028126, encodeId=ddd3202812633, content=<a href='/topic/show?id=38538e43be' target=_blank style='color:#2F92EE;'>#HER2阴性乳腺癌#</a>, objectTitle=Int J Cancer：如何评估HER2阴性乳腺癌患者的长期预后？, objectType=article, longId=114639, objectId=ef9e114639a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ef9e114639a8, replyNumber=0, likeNumber=31, createdTime=2018-08-14, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ef9e114639a8, moduleTitle=Int J Cancer：如何评估HER2阴性乳腺癌患者的长期预后？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ef9e114639a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028124, encodeId=89a7202812434, content=<a href='/topic/show?id=38538e43be' target=_blank style='color:#2F92EE;'>#HER2阴性乳腺癌#</a>, objectTitle=Lancet Oncol：贝伐单抗添加到新辅助化疗对HER2阴性乳腺癌效果（ARTemis试验）, objectType=article, longId=50644, objectId=48375064403, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=48375064403, replyNumber=0, likeNumber=35, createdTime=2015-12-19, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=48375064403, moduleTitle=Lancet Oncol：贝伐单抗添加到新辅助化疗对HER2阴性乳腺癌效果（ARTemis试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=48375064403)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028123, encodeId=8c1f202812364, content=<a href='/topic/show?id=38538e43be' target=_blank style='color:#2F92EE;'>#HER2阴性乳腺癌#</a>, objectTitle=Lancet Oncol：贝伐珠单抗+二线化疗能改善HER2阴性乳腺癌PFS (TANIA研究), objectType=article, longId=41274, objectId=a319412e4e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a319412e4e0, replyNumber=0, likeNumber=41, createdTime=2014-12-29, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a319412e4e0, moduleTitle=Lancet Oncol：贝伐珠单抗+二线化疗能改善HER2阴性乳腺癌PFS (TANIA研究), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a319412e4e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028119, encodeId=2c9f20281192d, content=<a href='/topic/show?id=38538e43be' target=_blank style='color:#2F92EE;'>#HER2阴性乳腺癌#</a>, objectTitle=ASCO 2014：贝伐单抗在HER2阴性乳腺癌辅助治疗中失利（E5103研究）, objectType=article, longId=35032, objectId=208c35032c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=208c35032c3, replyNumber=0, likeNumber=38, createdTime=2014-07-25, rootId=0, userName=feather78, userId=3679417, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=208c35032c3, moduleTitle=ASCO 2014：贝伐单抗在HER2阴性乳腺癌辅助治疗中失利（E5103研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=208c35032c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028121, encodeId=0d8420281216d, content=<a href='/topic/show?id=38538e43be' target=_blank style='color:#2F92EE;'>#HER2阴性乳腺癌#</a>, objectTitle=索拉非尼不能延长HER2阴性乳腺癌患者无进展生存期（RESILIENCE研究）, objectType=article, longId=38348, objectId=af3d38348b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af3d38348b5, replyNumber=0, likeNumber=35, createdTime=2015-06-23, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af3d38348b5, moduleTitle=索拉非尼不能延长HER2阴性乳腺癌患者无进展生存期（RESILIENCE研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af3d38348b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028122, encodeId=322020281227a, content=<a href='/topic/show?id=38538e43be' target=_blank style='color:#2F92EE;'>#HER2阴性乳腺癌#</a>, objectTitle=维汀联合希罗达显著延长HER2阴性乳腺癌总生存期, objectType=article, longId=40815, objectId=525640815a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=525640815a4, replyNumber=0, likeNumber=43, createdTime=2015-06-08, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=525640815a4, moduleTitle=维汀联合希罗达显著延长HER2阴性乳腺癌总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=525640815a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028120, encodeId=1ea52028120dd, content=<a href='/topic/show?id=38538e43be' target=_blank style='color:#2F92EE;'>#HER2阴性乳腺癌#</a>, objectTitle=ASCO 2014：辅助化疗+贝伐珠单抗未使HER2阴性乳腺癌患者获益, objectType=article, longId=36094, objectId=bf553609449, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf553609449, replyNumber=0, likeNumber=42, createdTime=2014-10-06, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf553609449, moduleTitle=ASCO 2014：辅助化疗+贝伐珠单抗未使HER2阴性乳腺癌患者获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bf553609449)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028118, encodeId=7e6f2028118cd, content=<a href='/topic/show?id=38538e43be' target=_blank style='color:#2F92EE;'>#HER2阴性乳腺癌#</a>, objectTitle=Clin Cancer Res. ：在HER2阴性乳腺癌中鉴定出HER2阳性干细胞, objectType=article, longId=18292, objectId=0fad1829240, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0fad1829240, replyNumber=0, likeNumber=38, createdTime=2013-08-01, rootId=0, userName=feather78, userId=3679417, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0fad1829240, moduleTitle=Clin Cancer Res. ：在HER2阴性乳腺癌中鉴定出HER2阳性干细胞, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0fad1829240)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2028117, encodeId=6ddc202811e3a, content=<a href='/topic/show?id=38538e43be' target=_blank style='color:#2F92EE;'>#HER2阴性乳腺癌#</a>, objectTitle=Clin Cancer Res：研究揭示HER2阴性乳腺癌新的矛盾特征, objectType=article, longId=13939, objectId=f49713939ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f49713939ce, replyNumber=0, likeNumber=46, createdTime=2013-08-06, rootId=0, userName=feather78, userId=3679417, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f49713939ce, moduleTitle=Clin Cancer Res：研究揭示HER2阴性乳腺癌新的矛盾特征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f49713939ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

HER2阴性乳腺癌

2020-05-29

yangchou (审核中...)

前往app查看评论内容

全文收起 #HER2阴性乳腺癌#早期、局部晚期乳腺癌患者可以从新辅助化疗（NAC；手术前给予的治疗）中受益，主要是因为治疗期间和治疗后的肿瘤反应可以测量并用于为后续治疗决定提供信息。达到病理完全反应（pCR）的患者，主要是乳房和区域淋巴结中没有侵袭性癌症的患者，与NAC后残留癌症患者相比，转移性复发和死亡的风险显著降低。

2023-05-06

feather78 (审核中...)

前往app查看评论内容

#HER2阴性乳腺癌#

2022 ASCO：多西他赛和环磷酰胺辅助治疗HER2阴性乳腺癌的现实经验

2023-03-26

仁心济世 (审核中...)

前往app查看评论内容

#HER2阴性乳腺癌#

Chin J Cancer Res：阿帕替尼单药或联合治疗HER2阴性乳腺癌伴有胸壁转移患者的疗效：多中心II期临床研究

2022-09-24

feather78 (审核中...)

前往app查看评论内容

#HER2阴性乳腺癌#

Ther Adv Med Oncol：Bendamustine (苯达莫司汀)联合卡培他滨治疗经治的HER2阴性乳腺癌患者的疗效

2022-05-13

仁心济世 (审核中...)

前往app查看评论内容

#HER2阴性乳腺癌#

Br J Cancer：PI3K信号通路激活导致HER2阴性乳腺癌的eribulin耐药性的产生

2022-02-24

仁心济世 (审核中...)

前往app查看评论内容

#HER2阴性乳腺癌#

AACR 2020：Durvalumab+奥拉帕利+紫杉醇用于高危HER2阴性乳腺癌新辅助治疗创新高

2020-05-21

仁心济世 (审核中...)

前往app查看评论内容

#HER2阴性乳腺癌#

β受体拮抗剂是否可以延长晚期HER2阴性乳腺癌患者生存时间？

2017-09-30

仁心济世 (审核中...)

前往app查看评论内容

#HER2阴性乳腺癌#

Int J Cancer：如何评估HER2阴性乳腺癌患者的长期预后？

2018-08-14

仁心济世 (审核中...)

前往app查看评论内容

#HER2阴性乳腺癌#

Lancet Oncol：贝伐单抗添加到新辅助化疗对HER2阴性乳腺癌效果（ARTemis试验）

2015-12-19

仁心济世 (审核中...)

前往app查看评论内容

#HER2阴性乳腺癌#

Lancet Oncol：贝伐珠单抗+二线化疗能改善HER2阴性乳腺癌PFS (TANIA研究)

2014-12-29

feather78 (审核中...)

前往app查看评论内容

#HER2阴性乳腺癌#

ASCO 2014：贝伐单抗在HER2阴性乳腺癌辅助治疗中失利（E5103研究）

2014-07-25

仁心济世 (审核中...)

前往app查看评论内容

#HER2阴性乳腺癌#

索拉非尼不能延长HER2阴性乳腺癌患者无进展生存期（RESILIENCE研究）

2015-06-23

仁心济世 (审核中...)

前往app查看评论内容

#HER2阴性乳腺癌#

维汀联合希罗达显著延长HER2阴性乳腺癌总生存期

2015-06-08

仁心济世 (审核中...)

前往app查看评论内容

#HER2阴性乳腺癌#

ASCO 2014：辅助化疗+贝伐珠单抗未使HER2阴性乳腺癌患者获益

2014-10-06

feather78 (审核中...)

前往app查看评论内容

#HER2阴性乳腺癌#

Clin Cancer Res. ：在HER2阴性乳腺癌中鉴定出HER2阳性干细胞

2013-08-01

feather78 (审核中...)

前往app查看评论内容

#HER2阴性乳腺癌#

Clin Cancer Res：研究揭示HER2阴性乳腺癌新的矛盾特征

2013-08-06

科室
- - 订阅+
  - 更多科室
工具
服务